- Home
- AQMS vs JSPR Comparison
AQMS vs JSPR Comparison
Compare AQMS & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AQMS | JSPR |
|---|---|---|
| Founded | 2014 | 2018 |
| Country | United States | United States |
| Employees | N/A | 22 |
| Industry | Metal Fabrications | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.8M | 14.9M |
| IPO Year | 2015 | N/A |
Fundamental Metrics
Financial Performance| Metric | AQMS | JSPR |
|---|---|---|
| Price | $3.20 | $0.45 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 11 |
| Target Price | $12.00 | ★ $15.50 |
| AVG Volume (30 Days) | 103.6K | ★ 630.5K |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,100,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $600.00 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.34 | $0.42 |
| 52 Week High | $39.37 | $7.19 |
Technical Indicators
Market Signals| Indicator | AQMS | JSPR |
|---|---|---|
| Relative Strength Index (RSI) | 39.65 | 27.95 |
| Support Level | $2.51 | $0.42 |
| Resistance Level | $4.36 | $1.02 |
| Average True Range (ATR) | 0.32 | 0.09 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 45.61 | 7.53 |
Price Performance
Historical ComparisonAbout AQMS Aqua Metals Inc.
Aqua Metals Inc is engaged in the business of recycling Lead through a novel, proprietary and patent-pending process that it developed and named AquaRefining. The company's breakthrough, AquaRefining, delivers a product, at a higher yield, eliminates toxic waste, reduces permitting, and is less expensive to build than smelting. AquaRefining process will provide for the recycling of Lead acid batteries and the production of a pure grade Lead with a significantly lower cost of production, and with fewer environmental and regulatory issues, than conventional methods of Lead production.
About JSPR Jasper Therapeutics Inc.
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.